Introduction {#s1}
============

A key pathophysiological factor for youth with prediabetes and type 2 diabetes is pancreatic β-cell dysfunction against the backdrop of insulin resistance ([@B1],[@B2]). This impairment in glucose-stimulated β-cell function relative to insulin sensitivity (IS) can be detected even in youth with normal glucose tolerance (NGT) ([@B3],[@B4]). Short-term elevation of free fatty acids (FFAs) rapidly induces insulin resistance and β-cell lipotoxicity in youth ([@B5],[@B6]), signifying an important relationship between lipid metabolism, IS, and insulin secretion.

Given the important role of insulin in adipose tissue lipolysis ([@B7]), an accurate assessment of the relationship between adipose tissue IS (ATIS) and β-cell function would broaden our understanding of adipocyte and β-cell dysfunction in youth with prediabetes and type 2 diabetes. A recent study in obese adults suggests that relating adipose insulin resistance to glucose-stimulated insulin secretion provides a novel index of β-cell function ([@B8]). However, pathophysiological alterations in lipolysis and the balance between ATIS and β-cell function remain poorly elucidated in youth with dysglycemia.

Therefore, the purpose of this study was to examine the following: *1*) whole-body lipolysis, measured with \[^2^H~5~\]glycerol tracer, fasting and during a hyperinsulinemic-euglycemic clamp; *2*) lipid oxidation by indirect calorimetry; and *3*) the relationship between ATIS and β-cell function (i.e., adipose disposition index \[DI\]) in obese youth with impaired glucose tolerance (IGT) versus NGT.

Research Design and Methods {#s2}
===========================

Participants {#s3}
------------

A total of 138 adolescents (12 overweight and 126 obese) from our National Institutes of Health--funded K24 grant investigating insulin resistance in childhood were examined ([@B2]--[@B4]). The study was approved by the institutional review board of the University of Pittsburgh, and written informed parental consent and child assent were obtained from all participants.

Procedures {#s4}
----------

All participants underwent medical history, physical examination, and hematological and biochemical tests at the Pediatric Clinical and Translational Research Center of Children's Hospital of Pittsburgh. Pubertal development was assessed using Tanner criteria ([@B9]). Body composition was evaluated with dual-energy X-ray absorptiometry.

Metabolic Studies {#s5}
-----------------

Details of metabolic studies and biochemical measurements (glucose, insulin, FFA, lipids, HbA~1c~, and enrichments of glycerol and glucose) are described in the [Supplementary Data](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0551/-/DC1). In brief, all participants underwent a hyperinsulinemic-euglycemic clamp combined with stable isotopes and continuous indirect calorimetry and a hyperglycemic clamp after 10--12 h of fasting within a 1--4-week period in random order ([@B2],[@B3]). Fasting hepatic glucose production (HGP) was measured by \[6,6-^2^H~2~\]glucose and whole-body lipolysis by \[^2^H~5~\]glycerol as before ([@B10]). Peripheral IS was evaluated during a 3-h hyperinsulinemic (80 mU/m^2^/min)-euglycemic clamp ([@B2]--[@B4]). Substrate oxidation was measured by continuous indirect calorimetry (Deltatrac Metabolic Monitor; SensorMedics, Anaheim, CA) as previously described ([@B10]). First- and second-phase insulin secretion were assessed during a 2-h hyperglycemic (225 mg/dL) clamp ([@B2]--[@B4]). Glucose tolerance status was determined with HbA~1c~ and/or a 2-h oral glucose tolerance test (OGTT; 1.75 g/kg, maximum 75 g) ([@B11]). Fasting blood samples were obtained for lipid profile.

Calculations {#s6}
------------

Endogenous glycerol appearance rate (GlyRa), indicative of whole-body lipolysis, was calculated as published by us ([@B10]). ATIS was calculated as 1/(GlyRa × insulin) at fasting and during hyperinsulinemic-euglycemic clamp steady state. Adipose DI was calculated as fasting ATIS × first-phase insulin secretion. Fasting HGP was calculated during the last 30 min of the 2-h isotope infusion ([@B12]). Hepatic IS was calculated as 1/(fasting HGP × insulin) ([@B13]). Insulin-stimulated glucose disposal (Rd) was calculated to be equal to the rate of exogenous glucose infusion during the final 30 min of the hyperinsulinemic-euglycemic clamp. Peripheral IS was calculated as (Rd/steady-state clamp insulin) × 100 ([@B12]). Insulin-stimulated carbohydrate and lipid oxidation rates were calculated from indirect calorimetry as before ([@B10]). Nonoxidative glucose disposal was estimated as total Rd − glucose oxidation rate. During the hyperglycemic clamp, first- and second-phase insulin were calculated during the first 10 min and 15--120 min, respectively ([@B12]).

Statistical Analysis {#s7}
--------------------

Independent-samples *t* tests and χ^2^ analyses were used to compare IGT versus NGT. Spearman correlation analysis was used for bivariate relationships between ATIS/adipose DI and metabolic characteristics. Data that did not meet normality assumptions were log~10~ transformed; untransformed data are presented for ease of interpretation. Data are mean ± SEM with *P* ≤ 0.05.

Results {#s8}
=======

Physical and Metabolic Characteristics of Obese Youth With IGT Versus NGT {#s9}
-------------------------------------------------------------------------

There were no differences in age, sex, race, Tanner stage, and percent body fat between the two groups. Youth with IGT versus NGT had higher BMI and fat mass. HbA~1c~, fasting glucose, and lipids were not different except for lower HDL and higher fasting insulin and a trend for higher FFA in youth with IGT ([Table 1](#T1){ref-type="table"}).

###### 

Physical and metabolic characteristics in obese youth with IGT vs. NGT

                                                NGT (*n* = 97)            IGT (*n* = 41)          *P*
  --------------------------------------------- ------------------------- ----------------------- -------
  Physical characteristics                                                                        
   Age (years)                                  14.3 ± 0.2                14.7 ± 0.4              NS
   Sex (male/female), *n* (%)                   35 (36)/62 (64)           9 (22)/32 (78)          NS
   Race (AA/AW), *n* (%)                        46 (47)/51 (53)           13 (32)/28 (68)         NS
   Tanner stage (III/IV/V), *n* (%)             26 (27)/18 (18)/53 (55)   4 (10)/7 (17)/30 (73)   NS
   BMI (kg/m^2^)                                34.4 ± 0.6                36.9 ± 1.0              0.029
   BMI *z* score                                2.20 ± 0.05               2.35 ± 0.05             0.018
   Total fat mass (kg)                          38.5 ± 1.3                43.2 ± 1.7              0.046
   Fat-free mass (kg)                           48.0 ± 1.0                51.0 ± 1.6              NS
   Percent body fat (%)                         42.4 ± 0.8                44.5 ± 0.8              NS
   Total cholesterol (mg/dL)                    161.6 ± 3.2               172.9 ± 5.1             NS
   Triglyceride (mg/dL)                         116.2 ± 5.5               140.4 ± 13.7            NS
   HDL (mg/dL)                                  41.7 ± 0.9                38.2 ± 1.4              0.034
   LDL (mg/dL)                                  96.8 ± 2.9                106.9 ± 4.7             NS
   VLDL (mg/dL)                                 23.2 ± 1.1                26.1 ± 2.4              NS
  Metabolic characteristics                                                                       
   HbA~1c~ (%)                                  5.26 ± 0.04               5.35 ± 0.07             NS
   Fasting glucose (mg/dL)                      95.8 ± 0.6                97.5 ± 1.2              NS
   Fasting insulin (µU/mL)                      35.6 ± 1.6                49.6 ± 4.6              0.002
   Fasting FFAs (mmol/L)                        0.30 ± 0.01               0.35 ± 0.02             0.070
   Steady-state glucose (mg/dL)                 100.6 ± 0.2               100.3 ± 0.3             NS
   Steady-state insulin (µU/mL)                 283.5 ± 9.5               308.0 ± 13.4            NS
  Hyperglycemic clamp parameters                                                                  
   First-phase insulin concentration (µU/mL)    248.9 ± 19.6              219.3 ± 18.8            NS
   Second-phase insulin concentration (µU/mL)   285.5 ± 15.9              323.5 ± 28.7            NS

Values are reported as mean ± SEM or *n* (%). AA, African American; AW, American white.

Whole-Body Lipolysis, Lipid Oxidation, and ATIS {#s10}
-----------------------------------------------

Despite an ∼1.4-fold higher fasting insulin in youth with IGT, basal GlyRa was higher compared with NGT ([Fig. 1*A*](#F1){ref-type="fig"}). During the hyperinsulinemic-euglycemic clamp, there was a tendency for higher GlyRa in IGT versus NGT ([Fig. 1*A*](#F1){ref-type="fig"}). Expressing GlyRa per total body, per kilogram fat-free mass, or per kilogram fat mass yielded consistent results ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0551/-/DC1)). Fasting and clamp ATIS were lower in IGT versus NGT ([Fig. 1*B*](#F1){ref-type="fig"}). Lipid oxidation was similar at baseline but higher in IGT during hyperinsulinemia ([Fig. 1*C*](#F1){ref-type="fig"}). Percent suppression in lipid oxidation from baseline to clamp steady state was lower in youth with IGT versus NGT (NGT 59.6 ± 5.1 vs. IGT 35.1 ± 6.3%, *P* = 0.009).

![*A*: Whole-body lipolysis, fasting and during the last 30 min of the hyperinsulinemic-euglycemic clamp. *B*: ATIS, fasting and during the hyperinsulinemic-euglycemic clamp. *C*: Lipid oxidation, fasting and during the hyperinsulinemic-euglycemic clamp in youth with IGT vs. NGT.](db170551f1){#F1}

β-Cell Function Relative to ATIS {#s11}
--------------------------------

Adipose DI was lower in IGT versus NGT ([Fig. 2*A*](#F2){ref-type="fig"}). The hyperbolic curves (ATIS × first-phase insulin) represent the nonlinear fitted regression lines derived from individual data points of NGT (*R*^2^ = 0.139) and IGT (*R*^2^ = 0.113, all *P* \< 0.05) ([Fig. 2*B*](#F2){ref-type="fig"}). Adipose DI using second-phase insulin yielded consistent results (NGT 2,963.7 ± 163.1 vs. IGT 2,192.2 ± 269.1 \[µmol/kg/min\]^−1^, *P* = 0.001). The lower adipose DI in IGT versus NGT mirrors the glucose DI ([Fig. 2*C* and *D*](#F2){ref-type="fig"}).

![*A*: Adipose DI, i.e., β-cell function relative to ATIS. *B*: Hyperbolic relationship between ATIS and first-phase insulin concentration during the hyperglycemic clamp. *C*: Glucose DI, i.e., β-cell function relative to peripheral IS. *D*: Hyperbolic relationship between peripheral IS and first-phase insulin concentration during the hyperglycemic clamp in youth with IGT vs. NGT.](db170551f2){#F2}

Hepatic and Peripheral IS, Insulin Secretion, and Glucose DI {#s12}
------------------------------------------------------------

Fasting HGP was not different between the two groups; however, hepatic IS was lower in IGT versus NGT ([Table 2](#T2){ref-type="table"}). Insulin-stimulated total, oxidative, and nonoxidative glucose disposal and peripheral IS were lower in IGT versus NGT ([Table 2](#T2){ref-type="table"}). During the hyperglycemic clamp, first- and second-phase insulin were not different between the two groups ([Table 1](#T1){ref-type="table"}). However, glucose DI (peripheral IS × first-phase insulin) was lower in youth with IGT ([Fig. 2*C*](#F2){ref-type="fig"}).

###### 

Hepatic and peripheral tissue IS of glucose metabolism in obese youth with IGT vs. NGT

                                                                 NGT (*n* = 97)   IGT (*n* = 41)   *P*
  -------------------------------------------------------------- ---------------- ---------------- ----------
  Fasting HGP (mg/kg/min)                                        2.3 ± 0.1        2.4 ± 0.1        NS
  Hepatic IS (mg/kg/min ⋅ µU/mL)^−1^                             16.0 ± 0.8       11.8 ± 1.0       0.001
  Insulin-stimulated glucose disposal (mg/kg/min)                6.1 ± 0.2        4.7 ± 0.3        \<0.0001
  Insulin-stimulated glucose oxidation (mg/kg/min)               2.7 ± 0.1        2.3 ± 0.1        0.006
  Insulin-stimulated nonoxidative glucose disposal (mg/kg/min)   3.3 ± 0.2        2.6 ± 0.3        0.028
  Peripheral IS (mg/kg/min per µU/mL)                            2.5 ± 0.2        1.7 ± 0.2        0.001

Values are reported as the mean ± SEM.

Correlations of ATIS and Adipose DI With Glucose Metabolism {#s13}
-----------------------------------------------------------

ATIS correlated with hepatic IS (*r* = 0.711, *P* \< 0.0001) and peripheral IS (*r* = 0.615, *P* \< 0.0001). The suppression in lipolysis during hyperinsulinemia correlated with total glucose disposal (*r* = 0.383, *P* \< 0.0001) and oxidative (*r* = 0.230, *P* = 0.009) and nonoxidative disposal (*r* = 0.334, *P* \< 0.0001). Adipose DI correlated with glucose DI in the total group (*r* = 0.702, *P* \< 0.0001) and in each group separately (NGT *r* = 0.688, *P* \< 0.0001; IGT *r* = 0.612, *P* \< 0.0001).

Conclusions {#s14}
===========

We show that obese youth with IGT versus NGT have higher whole-body lipolysis and lower ATIS at baseline despite ∼40% higher fasting insulin concentrations. Further, youth with IGT have impaired insulin action in suppressing lipid oxidation. Together with adipose tissue insulin resistance, adipose DI is lower by ∼43% in IGT versus NGT and correlates directly with glucose DI (β-cell function relative to peripheral/skeletal muscle IS).

To date, there are no pediatric data with respect to the quantitative relationship of adipose tissue lipolysis, ATIS, and β-cell function in youth with prediabetes or type 2 diabetes. Studies in adults show adipocyte dysfunction in obesity, prediabetes, and type 2 diabetes ([@B14]--[@B16]). A study in pediatrics using FFA and insulin concentrations as surrogate markers of adipose tissue insulin resistance demonstrated worsening adipose insulin resistance, manifested in greater FFA area under the OGTT curve, with worsening glucose tolerance ([@B17]). Herein we hypothesized that youth with IGT will manifest not only dysregulation of lipolysis and impaired ATIS but also impaired β-cell function or compromised adipose DI.

Using \[^2^H~5~\]glycerol for robust assessment of whole-body lipolysis ([@B18]), our observation of increased fasting lipolysis (∼22%) and reduced ATIS (∼38%) in youth with IGT versus NGT is in agreement with adult studies ([@B8],[@B14]--[@B16]) and the only pediatric publication ([@B17]). However, most of these studies used fasting plasma FFA to generate an index of adipose tissue insulin resistance ([@B14]--[@B17]). A study in adults using \[1-^14^C\]palmitate turnover ([@B8]) showed increased fasting lipolysis and higher adipose insulin resistance in subjects with type 2 diabetes versus their counterparts without diabetes, consistent with our fasting data in youth with IGT versus NGT. With concomitant fasting hyperinsulinemia, our findings of higher lipolysis but similar HGP in IGT versus NGT suggest that dysregulation of lipolysis could be an early/sensitive sign of metabolic disturbances. Given that obese youth with NGT in our study have 32--45% higher fasting GlyRa compared with what is reported in obese adults ([@B19],[@B20]), future studies should evaluate lipid metabolism between phenotypically matched adults and youth along the spectrum of glucose tolerance. This may shed light on our recent observation that obese adolescents with IGT have 50% lower hepatic and peripheral IS than equally obese adults with IGT ([@B21]). Besides increased fasting lipolysis, youth with IGT have diminished suppression in lipolysis (∼22% lower ATIS) and in lipid oxidation (∼41% lower suppression from baseline) during hyperinsulinemia.

Only one study in adults examined the relationship between ATIS, derived from either palmitate turnover or fasting FFA, and insulin secretion, but during an OGTT, in adults without diabetes versus with diabetes ([@B8]). Our study supplements the adult literature and advances the pediatric literature by the novel observation that youth with IGT versus NGT have an impaired β-cell function relative to ATIS, with 43% lower adipose DI. Besides lipotoxicity potentially impairing β-cell function ([@B5],[@B6]), one could speculate that adipocyte dysfunction through altered secretion of anti/proinflammatory adipokines could contribute to β-cell dysfunction ([@B17],[@B22]). This lower adipose DI is commensurate with previously reported impaired β-cell function relative to peripheral IS with respect to glucose metabolism in youth with IGT ([@B2]). Thus, adipose DI can be yet another index of β-cell function that deteriorates from NGT to IGT, mirroring the declining glucose DI.

When we assessed the relationship between whole-body lipolysis and ATIS with pathophysiological alterations of glucose metabolism, hepatic and peripheral IS showed strong correlations with ATIS, pointing to a global insulin resistance in youth with IGT. Additionally, increased fat oxidation during the clamp, characteristic of youth with IGT, correlated with decreased peripheral IS (*r* = −0.337, *P* \< 0.0001), suggestive of a tight relationship between lipolysis/fat oxidation and glucose metabolism. In high-fat diet--fed mice, partial inhibition of lipolysis improves glucose metabolism and IS, attesting to a causal relationship between the two ([@B23]).

The strengths of the present investigation include the following: *1*) the use of \[^2^H~5~\]glycerol to examine whole-body lipolysis; *2*) examining youth with IGT instead of type 2 diabetes to avoid confounding modulators of ATIS and β-cell function such as various treatments, weight loss preceding the diagnosis of type 2 diabetes, and degree of hyperglycemia and lipemia; *3*) evaluating whole-body lipolysis not only during fasting but also during hyperinsulinemia; *4*) complementing the evaluation of lipolysis with measurement of fat oxidation using calorimetry; *5*) a first-time characterization of the relationship between ATIS and β-cell function; and *6*) complementing ATIS evaluation with examination of peripheral IS and β-cell function with respect to glucose metabolism. Potential perceived limitations would be that in order to minimize participant burden, we did not use a multistep (low and high dose) hyperinsulinemic clamp, which would have prolonged the duration of the clamp, to measure submaximal suppression of lipolysis ([@B24]). A recent study, however, shows a strong correlation between ATIS measured by a one-step hyperinsulinemic-euglycemic clamp versus a multistep clamp ([@B25]). Another alleged weakness could be that we did not study youth with type 2 diabetes; however, our rational for not doing so is listed under strengths. We believe that IGT is a "virgin" state of type 2 diabetes that allows one to examine pathopysiological alterations "unadulterated" with treatment or gluco/lipotoxicity.

In summary, obese youth with IGT versus NGT are resistant to the antilipolytic effect of insulin in addition to having skeletal muscle insulin resistance. This insulin resistance is combined with impaired β-cell function relative to ATIS and coexists with β-cell dysfunction with respect to glucose metabolism. These findings signify global impairments in IS and in β-cell function in obese youth with IGT. Longitudinal studies are needed to determine the impact of adipocyte dysfunction on the natural history of prediabetes and type 2 diabetes in youth, and the effect of therapeutic interventions that target inhibition of lipolysis to prevent and/or treat type 2 diabetes.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0551/-/DC1>.
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